niacinamide has been researched along with Astrocytoma in 9 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial." | 9.19 | Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 7.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| "Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit." | 6.79 | Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. ( Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D, 2014) |
| "This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial." | 5.19 | Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014) |
| "MOGGCCM (anaplastic astrocytoma) and T98G (glioblastoma multiforme) cell lines incubated with sorafenib and/or Temozolomide were used in the experiments." | 3.85 | Temozolomide and sorafenib as programmed cell death inducers of human glioma cells. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A, 2017) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 3.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| "Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit." | 2.79 | Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. ( Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D, 2014) |
| "Malignant primary brain tumors have hitherto been incurable." | 1.30 | Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors. ( Brun, A; Kjellén, E; Pero, RW; Persson, RB; Salford, LG, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jakubowicz-Gil, J | 2 |
| Bądziul, D | 2 |
| Langner, E | 2 |
| Wertel, I | 2 |
| Zając, A | 1 |
| Rzeski, W | 2 |
| Suzuki, Y | 1 |
| Nakamura, Y | 1 |
| Yamada, K | 1 |
| Kurabe, S | 1 |
| Okamoto, K | 1 |
| Aoki, H | 1 |
| Kitaura, H | 1 |
| Kakita, A | 1 |
| Fujii, Y | 1 |
| Huber, VJ | 1 |
| Igarashi, H | 1 |
| Kwee, IL | 1 |
| Nakada, T | 1 |
| Sherman, JH | 1 |
| Kirzner, J | 1 |
| Siu, A | 1 |
| Amos, S | 1 |
| Hussaini, IM | 1 |
| Legault, G | 2 |
| Kieran, MW | 1 |
| Scott, RM | 1 |
| Chordas, C | 1 |
| Milla, SS | 2 |
| Karajannis, MA | 2 |
| Fisher, MJ | 1 |
| Cohen, KJ | 1 |
| Wisoff, JH | 1 |
| Harter, DH | 1 |
| Goldberg, JD | 1 |
| Hochman, T | 1 |
| Merkelson, A | 1 |
| Bloom, MC | 1 |
| Sievert, AJ | 1 |
| Resnick, AC | 1 |
| Dhall, G | 1 |
| Jones, DT | 1 |
| Korshunov, A | 1 |
| Pfister, SM | 1 |
| Eberhart, CG | 1 |
| Zagzag, D | 1 |
| Allen, JC | 1 |
| Sie, M | 1 |
| den Dunnen, WF | 1 |
| Lourens, HJ | 1 |
| Meeuwsen-de Boer, TG | 1 |
| Scherpen, FJ | 1 |
| Zomerman, WW | 1 |
| Kampen, KR | 1 |
| Hoving, EW | 1 |
| de Bont, ES | 1 |
| Salford, LG | 1 |
| Brun, A | 1 |
| Kjellén, E | 1 |
| Pero, RW | 1 |
| Persson, RB | 1 |
| Coper, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas[NCT01338857] | Phase 2 | 12 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Sorafenib ineffective for tx of recurrent or progressive PLGA) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Determination of tumor response (CR, PR, SD) will be defined based on the comparison of the baseline MRI performed at study entry to the subsequent MRI which demonstrated best response. PR will be defined by a >15% decrease in tumor volume, as measured by 3D volumetric analysis. (NCT01338857)
Timeframe: MRIs performed after every 3rd 28-day cycle and off-study
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar) | 1 |
To estimate the objective response rates to sorafenib in children and young adults with low-grade astrocytomas, including optic pathway gliomas. (NCT01338857)
Timeframe: one year
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar) | 1 |
3 trials available for niacinamide and Astrocytoma
| Article | Year |
|---|---|
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; | 2014 |
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
Topics: Adolescent; Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child, Preschool; Female; | 2014 |
[Studies of the NAD(P) glycohydrolase activity in human brain tumors].
Topics: Adenoma, Chromophobe; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Enzyme Induction; Epen | 1967 |
6 other studies available for niacinamide and Astrocytoma
| Article | Year |
|---|---|
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Line, Tumor; Dacarbazine; Gene Expression Regula | 2017 |
Aquaporin Positron Emission Tomography Differentiates Between Grade III and IV Human Astrocytoma.
Topics: Adult; Aged; Aged, 80 and over; Aquaporins; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Female; | 2018 |
Sorafenib tosylate as a radiosensitizer in malignant astrocytoma.
Topics: Astrocytoma; Blotting, Western; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niacinamide | 2014 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combinatio | 2014 |
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Epe | 2015 |
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Topics: Animals; Astrocytoma; Brain Neoplasms; Cell Division; Combined Modality Therapy; DNA Repair; Enzyme | 1997 |